Skip to main content
. 2021 Sep 25;19:146. doi: 10.1186/s12969-021-00637-8

Fig. 1.

Fig. 1

JAK-STAT pathway with JAK inhibitor targets. The activation of the JAK-STAT pathway after IFN type 1 has engaged with the associated receptor, IFNR. This induces the transcription of proteins. Tofacitinib inhibits JAK1/2/3. Ruxolitinib and Baricitinib inhibit JAK 1/2, inhibtion prevents STAT phosphorylation, dimeraziation and transolcation into the nucleuse. This in turn stops the transcription of pro-inflammatory proteins